Copyright
©The Author(s) 2020.
World J Gastroenterol. Oct 7, 2020; 26(37): 5534-5542
Published online Oct 7, 2020. doi: 10.3748/wjg.v26.i37.5534
Published online Oct 7, 2020. doi: 10.3748/wjg.v26.i37.5534
Table 2 Continued summary of expert opinions and guidelines
General recommendations | Serious COVID-19 disease risk: Highest risk | Moderate risk | Lowest risk | |
BSG | Continue current medications; Avoid corticosteroids if possible Observe “shielding” while prednisone dose ≥ 20 mg daily; Initiation of IMM monotherapy not advised; Consider stopping thiopurines in older patients or those with significant comorbidity who are in sustained remission; Consider monotherapy with anti-TNF; Consider adalimumab over infliximab to promote home care; Early use of therapeutic drug monitoring; Do not recommend switching from IV to S/C | IBD and a comorbidity; Hypertension Diabetes; Age ≥ 70 yr; AND one from “Moderate Risk” column OR; Moderate to severely active disease; ≥ 20 mg prednisolone or equivalent; New biologic < 6 wk; Moderate to severely active disease NOT controlled on Moderate risk Rx; Short bowel syndrome ON nutritional support; Requirement for Parenteral nutrition | Anti-TNF monotherapy; Biologic plus immunomodulator in stable patients; Ustekinumab; Vedolizumab; Thiopurines; Methotrexate; Calcineurin inhibitors (tacrolimus or ciclosporin); Janus kinase inhibitors (tofacitinib); Immunosuppressive trial medication; Mycophenolate mofetil; Thalidomide; Prednisolone < 20 mg or equivalent per day | 5-ASA users; Rectal therapies; Orally administered topically acting steroids (budesonide or beclometasone); Therapies for bile acid diarrhoea (cholestyramine, colesevelam, colestipol); Antidiarrhoeals (e.g., loperamide); Antibiotics for bacterial overgrowth or perianal disease |
CCF | Stay on your medications; Do not skip infusion appointments; Consider rescheduling non urgent endoscopic procedures |
- Citation: Sultan K, Mone A, Durbin L, Khuwaja S, Swaminath A. Review of inflammatory bowel disease and COVID-19. World J Gastroenterol 2020; 26(37): 5534-5542
- URL: https://www.wjgnet.com/1007-9327/full/v26/i37/5534.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i37.5534